News
We bring you up to date at all times: Discover the latest industry news from biotechnology, pharmaceuticals and life sciences. Researched by us so you don't have to.
Selected departments
Selected industries
Companies
The Who's Who of Life Sciences: Discover companies from all over the world. Here you can easily find the provider matching your search, including contact options.
Selected countries
Selected companies
Products
The first stop for your procurement process: discover innovative products for lab and process that make your everyday life easier and solve even complex challenges.
Products of selected companies
Market overviews
Direct comparison of products for laboratory and process: Use the comprehensive market overviews to compare products according to your requirements and obtain further information from suppliers.
White papers
What could be better than an application problem that has already been solved by others? Tap into in-depth application knowledge from proven experts. Conveniently via download to your device.
Most read white papers
White papers of selected companies
Knowledge & education
Question. Answer. Find articles on 57,945 keywords in life science, biotech, pharma, biology and related science disciplines in the encyclopedia..
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Note
The function "Store search" is only available to registered users.
Important information
Currently, you are not logged in to my.bionity.com. Therefore, you can remember a maximum of 5 contents.
FILTER
Refine your search with the following facets to narrow down your results.
22-Jan-2008 - Royal DSM N.V. and the French starch and starch-derivatives company ROQUETTE have joined forces to implement and commercialize the fermentative production of biorenewable succinic acid, which -amongst other applications- opens the possibility to produce bio-based performance materials. By the end ...
05-Nov-2007 - DSM Biologics, a business unit of DSM Pharmaceutical Products and Crucell N.V. announced that they have signed a non-exclusive PER.C6® technology research licensing agreement with Brazilian-based Recepta Biopharma S.A. This agreement allows Recepta Biopharma to use the PER.C6® technology to ...
07-Sep-2007 - DSM Venturing, the corporate venturing unit of Royal DSM N.V., announced that it has made an equity investment of EUR 2 million in Jurilab Oy, a Finnish company specialized in the discovery of gene-disease associations and their application to healthcare. Following investments in Sciona and ...
16-Jul-2007 - Following the installation of a Corporate Scientific Advisory Board in June 2007, DSM has now decided to establish a Biomedical Scientific Advisory Board to support the company in its ambitions to become a world leader in biomedical materials. The Biomedical Scientific Advisory Board will consist ...
08-Jun-2007 - Royal DSM N.V. and Crucell N.V. announced a non-exclusive PER.C6® research licensing deal with Goettingen, Germany-based Sartorius Biotech GmbH. Sartorius will use Crucell's key technology to evaluate monoclonal antibodies produced using PER.C6® cells for calibrating and testing equipment ...
06-Jun-2007 - Royal DSM N.V. announces that AstraZeneca has acquired the biologics manufacturing facility in Montreal, Canada, from DSM Biologics Inc. This transaction will lead to a small book profit for DSM. The facility, occupying 66,000 sq. ft, will be used to manufacture antibody drug candidates for ...
21-Feb-2007 - DSM Venturing, the corporate venturing unit of Royal DSM N.V., announced that it has made an equity investment in Harland Medical Systems, Inc., an emerging US company that is marketing technologies and solutions in medical coating applications. This is DSM's third investment in a biomedical ...
16-Feb-2007 - Royal DSM N.V. and Crucell N.V. announced fermentation yields of more than 10 grams per liter for monoclonal antibodies, a major breakthrough in the development of their PER.C6 technology platform. Early last year, DSM and Crucell announced their major objectives for their PER.C6 development ...
09-Feb-2007 - DSM Biologics, a business unit of DSM Pharmaceuticals, and Dutch biotechnology company Crucell N.V. announced that they have further intensified their PER.C6® collaboration, by executing an agreement to expand the existing commercial relationship to include new classes of proteins, including ...
31-Jan-2007 - DSM is publishing a paper in the February 2007 issue of "Nature Biotechnology" announcing the release of the DNA sequence of the fungus Aspergillus niger. The article - which has 69 co-authors - is the result of a research project carried out by DSM in which twenty-nine international research ...
© 1997-2024 LUMITOS AG, All rights reserved